Q.42 Which of the following statement(s) is(are) TRUE about fluoroquinolone drugs?
(A) They contain quinolone ring(s)
(B) They inhibit RNA polymerase
(C) They bind to bacterial topoisomerase
(D) They bind to 23S rRNA within the 50S ribosome subunit

Fluoroquinolone drugs are broad-spectrum antibiotics characterized by a fluorine-substituted quinolone structure, primarily targeting bacterial DNA replication enzymes. Statements (A) and (C) are true, as they contain quinolone rings and bind to bacterial topoisomerases like DNA gyrase and topoisomerase IV.​

Option Analysis

Option (A): Fluoroquinolones contain a core quinolone ring (bicyclic structure with a fluorine at C-6), distinguishing them from earlier quinolones like nalidixic acid. This structural feature enhances antibacterial potency and membrane permeability.​

Option (B): False; fluoroquinolones do not inhibit RNA polymerase, which is targeted by rifampicin. Their action focuses on DNA-related enzymes.​

Option (C): True; they bind to bacterial topoisomerases (DNA gyrase and topoisomerase IV), stabilizing enzyme-DNA cleavage complexes, blocking DNA replication, and causing cell death.​

Option (D): False; binding to 23S rRNA in the 50S ribosomal subunit is the mechanism of macrolides like erythromycin, not fluoroquinolones.​

Fluoroquinolone drugs represent a cornerstone in antibacterial therapy, especially relevant for competitive exams like IIT JAM Biotechnology. These synthetic antibiotics feature a quinolone ring structure with a key fluorine substitution, enabling broad-spectrum activity against Gram-positive and Gram-negative bacteria. Understanding their fluoroquinolone antibiotics mechanism of action—centered on bacterial topoisomerase inhibition—is crucial for mastering microbiology and pharmacology sections.​

Core Structure of Fluoroquinolone Drugs

Fluoroquinolone drugs contain one or more quinolone rings, a bicyclic system with a carboxyl at C-3, keto at C-4, and fluorine at C-6 for enhanced potency. Examples include ciprofloxacin and levofloxacin, derived from nalidixic acid. This quinolone ring structure improves cell penetration and enzyme affinity.​

Mechanism of Action

Fluoroquinolone drugs bind bacterial topoisomerase enzymes (DNA gyrase: GyrA2GyrB2; topoisomerase IV: ParC2ParE2), trapping cleaved DNA intermediates. This halts replication and transcription, leading to double-strand breaks and bactericidal effects. They do not target RNA polymerase or ribosomes.​

Common Misconceptions

• No RNA polymerase inhibition (that’s rifampin).

• No 23S rRNA binding (macrolide action).
  Resistance arises from target mutations or efflux pumps, not altering these core truths.​